Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non‐small cell lung cancer
Asia-Pacific Journal of Clinical Oncology · 2024
DOI: 10.1111/ajco.13992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Choong-Won Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Salvage Therapy, Lung Neoplasms, Radiosurgery, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Purpose
Stereotactic ablative radiotherapy (SABR) for early‐stage lung cancer has shown promising results; however, regional recurrence (RR) development is not uncommon, and salvage treatment strategies have not been established. We aimed to investigate treatment patterns, prognostic factors, and survival outcomes. Materials and methods A retrospective analysis of 391 patients who underwent SABR for primary lung cancer from 2012 to 2019 was performed. Among these patients, 90 patients showed recurrence, including local recurrence ( n = 9), RR ( n = 33), distant metastasis (DM) ( n = 57), and RR with simultaneous DM ( n = 8). The median follow‐up duration was 17.3 months.
Results
The median age was 75 years, and most patients underwent primary SABR due to poor lung function (69.7%). Various salvage treatments were performed in cases of RR, including chemotherapy ( n = 15), radiotherapy ( n = 7), concurrent chemoradiotherapy ( n = 2), and best supportive care ( n = 9). The median overall survival (OS) and post‐recurrence OS (PR‐OS) were 22.9 and 11.2 months, respectively. In multivariate analysis, age ≤75 years (HR = 0.36, p = 0.040), isolated recurrence (HR = 0.34, p = 0.037), and radiotherapy without chemotherapy (HR = 0.25, p = 0.024) were significant prognostic factors for PR‐OS.
Conclusions
Despite various salvage treatments, PR‐OS was less than 1 year after RR in our frail patients group who underwent primary SABR. The toxicities of salvage chemotherapy could be quite severe; thus, careful patient selection is required. Further research is needed to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
- Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Lee, C. W., Kim, B. H., Wu, H. G., & Kim, H. J. (2024). Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non‐small cell lung cancer. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13992
Vancouver
Lee CW, Kim BH, Wu HG, Kim HJ. Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non‐small cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.13992
BibTeX
@article{Lee2024,
author = {Lee, Choong-Won and Kim, Byoung Hyuck and Wu, Hong-Gyun and Kim, Hak Jae},
title = {Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non‐small cell lung cancer},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2024},
doi = {10.1111/ajco.13992}
}
EUVIMED